ArticleBiomedicines2022
Fecal Microbiota Transplantation in Patients Co-Infected with SARS-CoV2 and
Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Safety and efficacy of fecal microbiota transplantation for viral diseases: A systematic review of clinical trials.PloS one · 2024Pooled it
- Predictors of RecurrentDiagnostics (Basel, Switzerland) · 2026Article
- Targeting Gut-Lung Crosstalk in Acute Respiratory Distress Syndrome: Exploring the Therapeutic Potential of Fecal Microbiota Transplantation.Pathogens (Basel, Switzerland) · 2025Review
- The Gut Microbiome in Enteric Viral Infections: Underlying Mechanisms and Therapeutic Approaches.Microorganisms · 2025Review
- Importance of Fecal Microbiota Transplantation and Molecular Regulation as Therapeutic Strategies in Inflammatory Bowel Diseases.Nutrients · 2024Review
- Bacterial Infections, Trends, and Resistance Patterns in the Time of the COVID-19 Pandemic in Romania-A Systematic Review.Antibiotics (Basel, Switzerland) · 2024Review
- Optimizing Diagnosis and Management of Ventilator-Associated Pneumonia: A Systematic Evaluation of Biofilm Detection Methods and Bacterial Colonization on Endotracheal Tubes.Microorganisms · 2024Review
- Reduction of product composition variability using pooled microbiome ecosystem therapy and consequence in two infectious murine models.Applied and environmental microbiology · 2024Article
- A Real-World Study on the Clinical Characteristics, Outcomes, and Relationship between Antibiotic Exposure andAntibiotics (Basel, Switzerland) · 2024Article
- Fecal microbiota transplantation for glaucoma; a potential emerging treatment strategy.Current research in microbial sciences · 2024Review
- A Pharmacovigilance Study Regarding the Risk of Antibiotic-AssociatedPharmaceuticals (Basel, Switzerland) · 2023Article
- The Significance of Preoperative Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Systemic Inflammatory Index (SII) in Predicting Severity and Adverse Outcomes in Acute Calculous Cholecystitis.Journal of clinical medicine · 2023Article
- Laparoscopic Adrenalectomy: Tailoring Approaches for the Optimal Resection of Adrenal Tumors.Diagnostics (Basel, Switzerland) · 2023Article
- Fecal Microbiota Transplantation in Liver Cirrhosis.Biomedicines · 2023Review
- Severe Acute Ischemia of Glans Penis after Achieving Treatment with Only Hyperbaric Oxygen Therapy: A Rare Case Report and Systematic Literature Review.Journal of personalized medicine · 2023Review
- Exploring the Potential of Fecal Microbiota Transplantation as a Therapy in Tuberculosis and Inflammatory Bowel Disease.Pathogens (Basel, Switzerland) · 2023Review
- Therapeutic Perspectives for Microbiota Transplantation in Digestive Diseases and Neoplasia-A Literature Review.Pathogens (Basel, Switzerland) · 2023Review
- Fecal Microbiota Transplantation in Inflammatory Bowel Disease.Biomedicines · 2023Review
- The impact of the COVID-19 pandemic onTherapeutic advances in gastroenterology · 2023Review
- Development and management of gastrointestinal symptoms in long-term COVID-19.Frontiers in microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 1 institution in 1 country.
Funding
Abstract
Background: The COVID-19 pandemic has challenged the treatment of Clostridioides Difficile (CD)-infected patients given the increasing number of co-infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this context, fecal microbiota transplantation (FMT) shows promise in modulating the immune system’s function and alleviating the burdens associated with this condition. Methods: To achieve this goal, we performed a comparative, retrospective, single-center study on 86 patients (admitted between January 2020 and March 2022). We based our approach on specific inclusion criteria: 1. The study group included 46 co-infected patients (COVID-19 and CD) receiving antibiotics and FMT; 2. In the control group, 40 co-infected patients received antibiotics only. Our results showed no significant group differences in terms of gender, age, risk factors such as cardiovascular and neurological diseases, type 2 diabetes, and obesity (p > 0.05), or in pre-treatment inflammatory status, evaluated by white blood cell (WBC) count and C-reactive protein (CRP) levels. We report a significant decrease in inflammatory syndrome (CRP, WBC) in coinfected patients receiving FMT in addition to antibiotics (p < 0.05), with a lower relapse rate and mitigation of cramping and abdominal pain (91.3%). In addition, a higher level of fibrinogen, persistent moderate abdominal pain (82.5%), and a significantly higher CD infection relapse rate (42.5%) were recorded in co-infected patients treated only with antibiotics (p < 0.05). Conclusion: Our study provides new data to support the multiple benefits of FMT in the case of COVID-19 and CD co-infection by improving patients’ quality of life and inflammatory syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.